ES2093593T1 - Proteinas obesas (ob) recombinantes. - Google Patents

Proteinas obesas (ob) recombinantes.

Info

Publication number
ES2093593T1
ES2093593T1 ES96106408T ES96106408T ES2093593T1 ES 2093593 T1 ES2093593 T1 ES 2093593T1 ES 96106408 T ES96106408 T ES 96106408T ES 96106408 T ES96106408 T ES 96106408T ES 2093593 T1 ES2093593 T1 ES 2093593T1
Authority
ES
Spain
Prior art keywords
proteins
recombinant
obese
recombinant obese
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES96106408T
Other languages
English (en)
Spanish (es)
Inventor
Arthur Campfield
Rene Devos
Yves Guisez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of ES2093593T1 publication Critical patent/ES2093593T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES96106408T 1995-05-05 1996-04-24 Proteinas obesas (ob) recombinantes. Pending ES2093593T1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43577795A 1995-05-05 1995-05-05
US48462995A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ES2093593T1 true ES2093593T1 (es) 1997-01-01

Family

ID=27030682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96106408T Pending ES2093593T1 (es) 1995-05-05 1996-04-24 Proteinas obesas (ob) recombinantes.

Country Status (35)

Country Link
US (1) US6025325A (OSRAM)
EP (1) EP0741187A2 (OSRAM)
JP (1) JP3244627B2 (OSRAM)
KR (1) KR100219970B1 (OSRAM)
CN (1) CN1157290A (OSRAM)
AR (1) AR003087A1 (OSRAM)
AU (1) AU688210B2 (OSRAM)
BG (1) BG62975B1 (OSRAM)
BR (1) BR9602166A (OSRAM)
CA (1) CA2175298A1 (OSRAM)
CZ (1) CZ129796A3 (OSRAM)
DE (1) DE741187T1 (OSRAM)
ES (1) ES2093593T1 (OSRAM)
GR (1) GR960300075T1 (OSRAM)
HR (1) HRP960213A2 (OSRAM)
HU (1) HU220093B (OSRAM)
IL (1) IL118059A0 (OSRAM)
IS (1) IS4343A (OSRAM)
MA (1) MA23856A1 (OSRAM)
MY (1) MY132189A (OSRAM)
NO (1) NO961796L (OSRAM)
NZ (1) NZ286466A (OSRAM)
OA (1) OA10362A (OSRAM)
PE (1) PE50897A1 (OSRAM)
PL (1) PL186568B1 (OSRAM)
RO (1) RO117177B1 (OSRAM)
RU (1) RU96109211A (OSRAM)
SG (1) SG49337A1 (OSRAM)
SK (1) SK56996A3 (OSRAM)
SV (1) SV1996000030A (OSRAM)
TN (1) TNSN96066A1 (OSRAM)
TR (1) TR199600357A2 (OSRAM)
TW (1) TW464655B (OSRAM)
UY (1) UY24219A1 (OSRAM)
YU (1) YU26596A (OSRAM)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
EP0612348B1 (en) 1991-11-04 2003-04-23 Genetics Institute, LLC Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
JP3717930B2 (ja) 1993-12-07 2005-11-16 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｂｍｐ−１２、ｂｍｐ−１３およびそれらの腱誘導組成物
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
NZ326592A (en) * 1995-12-27 2001-05-25 Genentech Inc Long half life derivatives of the OB protein and use in the treatment of OB gene related disorders
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) * 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
WO1997026916A1 (en) * 1996-01-25 1997-07-31 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US7067472B1 (en) * 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US20030036629A1 (en) * 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
EP2286847A1 (en) 1999-10-15 2011-02-23 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
US7446183B2 (en) 2000-06-16 2008-11-04 Asterion Limited Fusion protein comprising growth hormone and growth hormone receptor
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
ES2305246T3 (es) 2001-06-01 2008-11-01 Wyeth Composiciones para la administracion sistemica de secuencias que codifican proteinas oseas morfogeneticas.
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
AU2003225277A1 (en) * 2002-05-02 2003-11-17 Robert Harris Lipid removal from the body
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
KR20060133961A (ko) 2003-09-12 2006-12-27 와이어쓰 골형성 단백질 전달용의 주사 가능한 인산칼슘 고형 로드및 페이스트
JP5220410B2 (ja) 2004-07-19 2013-06-26 バイオコン・リミテッド インスリン−オリゴマー複合体、その処方物及び使用
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
MX2010003979A (es) * 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
JP5622720B2 (ja) * 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
EP2352510A4 (en) * 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
CN103547590B (zh) 2010-09-28 2017-11-28 埃格里昂制药股份有限公司 高度可溶性瘦蛋白
JP2014505060A (ja) 2011-01-26 2014-02-27 ノヴォ ノルディスク アー／エス レプチン誘導体
WO2021113434A1 (en) * 2019-12-03 2021-06-10 Rodan & Fields, Llc Peptides and compositions for inhibiting hair growth

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199337A (en) * 1978-10-06 1980-04-22 International Telephone And Telegraph Corporation Method of fabricating high strength optical preforms
US4666836A (en) * 1981-01-02 1987-05-19 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4757013A (en) * 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
US4643969A (en) * 1983-07-25 1987-02-17 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU3329895A (en) * 1994-08-17 1996-03-07 Rockefeller University, The Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5861485A (en) * 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
EP0725078A1 (en) * 1995-01-31 1996-08-07 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
EP0832220A1 (en) * 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
NZ326592A (en) * 1995-12-27 2001-05-25 Genentech Inc Long half life derivatives of the OB protein and use in the treatment of OB gene related disorders

Also Published As

Publication number Publication date
HUP9601120A2 (en) 1996-11-28
HRP960213A2 (en) 1997-10-31
US6025325A (en) 2000-02-15
SG49337A1 (en) 1998-05-18
TW464655B (en) 2001-11-21
RU96109211A (ru) 1998-10-27
SK56996A3 (en) 1997-04-09
BR9602166A (pt) 1998-01-13
SV1996000030A (es) 1999-01-14
RO117177B1 (ro) 2001-11-30
CA2175298A1 (en) 1996-11-06
NZ286466A (en) 1998-03-25
PL314051A1 (en) 1996-11-12
EP0741187A2 (en) 1996-11-06
BG62975B1 (bg) 2000-12-29
MX9601655A (es) 1997-07-31
CZ129796A3 (en) 1997-01-15
GR960300075T1 (en) 1996-12-31
YU26596A (sh) 1999-03-04
PL186568B1 (pl) 2004-01-30
JP3244627B2 (ja) 2002-01-07
AR003087A1 (es) 1998-07-08
AU5197896A (en) 1996-11-14
KR960041194A (ko) 1996-12-19
EP0741187A3 (OSRAM) 1996-12-11
KR100219970B1 (ko) 1999-10-01
MY132189A (en) 2007-09-28
HUP9601120A3 (en) 1999-07-28
HU220093B (hu) 2001-10-28
PE50897A1 (es) 1997-12-19
MA23856A1 (fr) 1996-12-31
BG100558A (bg) 1997-03-31
NO961796D0 (no) 1996-05-03
HU9601120D0 (en) 1996-06-28
JPH093098A (ja) 1997-01-07
IL118059A0 (en) 1996-08-04
IS4343A (is) 1996-12-09
OA10362A (fr) 2001-11-15
UY24219A1 (es) 2001-03-16
TR199600357A2 (tr) 1996-11-21
DE741187T1 (de) 1997-04-30
NO961796L (no) 1996-11-06
TNSN96066A1 (fr) 2005-03-15
AU688210B2 (en) 1998-03-05
CN1157290A (zh) 1997-08-20

Similar Documents

Publication Publication Date Title
ES2093593T1 (es) Proteinas obesas (ob) recombinantes.
PT850068E (pt) Extracto lipidico com actividade anti-inflamatoria
ATE163533T1 (de) Schwungphasensteuervorrichtung
CY1107533T1 (el) Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
HUP0103114A2 (hu) Apolipoprotein A-1 agonisták és alkalmazásuk diszlipidémiás rendellenességek kezelésében
HUP9901089A2 (hu) Gyógyászati sín, ehhez való fémlemez, ilyen sín alkalmazása
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
DE69942035D1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
WO2004000312A3 (de) Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2082587T3 (es) El uso de l-deprenyl para la fabricacion de un medicamento para el tratamiento de la enfermedad de cushing.
DE69209173D1 (de) Implantationzusammensetzungen, die biologisch aktive Proteine, Peptide oder Polypeptide enthalten
BR9815335A (pt) Uso de antagonistas de receptor de endotelina.
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
GR3032224T3 (en) Therapeutic agent for threatened abortion.
ECSP961740A (es) Proteinas obesas (ob) recombinantes ram 4105/175
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte
ES2103347T3 (es) Utilizacion de dicarbamato de 2-fenil-1,3-propanodiol en el tratamiento de enfermedades neurodegenerativas.
PT789761E (pt) Scf humano, uma respectiva variante de processamento, sua utilizacao farmaceutica
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)